Sanofi, GlaxoSmithKline Get India's Approval For Late-Stage Vaccine Trial

France's Sanofi and Britain's GlaxoSmithKline had in May kicked off global trials to include more than 35,000 adults to test their coronavirus vaccine.

Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday. France's Sanofi and Britain's GSK in May kicked off global trials to include more than 35,000 adults to test the shot. They hope to get approvals by the end of 2021 after early-stage results showed the vaccine produces a robust immune response. The Indian arm of the studies will enroll roughly 3,000 adults between the ages of 18 years and 55 years, according to India's clinical trial registry. The assessment is expected to run for a year and the first enrollment in India is shown to have been made on Tuesday.